About Iktos
Industry:
AI Drug Discovery
Founded:
2016
Founders:
Yann Gaston-Mathé, Quentin Perron, Nicolas Do Huu
Status:
Private
Funding & Growth
Total Raised:
€15.5M+
Stage:
Series A
Key Investors:
M Ventures
Debiopharm Innovation Fund
Omnes Capital
✓ Pros
- • Established generative-chemistry platform (since 2016)
- • AI plus wet-lab robotics under one roof
- • Backed by M Ventures and Debiopharm
- • Partnerships with major pharma
✗ Cons
- • Series-A-stage funding, smaller than some peers
- • Focused on small-molecule chemistry
- • Competitive AI-chemistry field
🧬 Bioinformatics Focus
Iktos builds deep-learning tools for small-molecule drug design.
Its Makya platform uses generative models to design novel, synthesizable molecules optimized across multiple parameters, while Spaya plans retrosynthetic routes.
The company pairs these with in-house robotics for automated synthesis and in-cellulo screening, closing the Design-Make-Test-Analyze loop.
Founded in Paris in 2016, it works with pharmaceutical, biotech and academic partners.